EGTX.ST

Healthcare Biotechnology

Egetis Therapeutics AB (publ)

SEK 9.72

+0.18 +1.89% today

Price History

Not enough data

Key Stats

Market Cap

4.52B

Avg Volume

1.74M

EPS

-SEK 1.00

52W High

SEK 9.79

52W Low

SEK 3.63

Div. Yield

0.0%

Analyst Ratings

Hold

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

81.00

P/B Ratio

9.38

P/S Ratio

68.48

EV/EBITDA

-10.85

EV/Revenue

62.66

Margins

Gross Margin 16.7%

Operating Margin (627.6%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Revenue Growth (YoY)

20.0%

Return on Equity

(96.9%)

Return on Assets

(34.4%)

Liquidity & Leverage

Current Ratio

1.49

Quick Ratio

1.46

Debt / Equity

0.14

Total Cash

378.40M

Total Debt

68.80M

About

Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is headquartered in Stockholm, Sweden.